Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
Elena LeinertLukas SchwentnerWolfgang JanniAchim WöckelSaskia-L HerbertDaniel HerrThorsten KühnFelix FlockRicardo FelberbaumRolf KreienbergVisnja FinkDavut DayanKristina ErnstSusanne Singernull nullPublished in: Breast cancer (Tokyo, Japan) (2022)
The prospective BRENDA II study demonstrates benefit in RFS by guideline adherence in adjuvant breast cancer treatment, indicating prospectively the value of internationally validated guidelines in breast cancer care.